English

Fulcrum Therapeutics, Inc.

EDGAR

FULC Registration statement (S-4) · filed 2026-09-02

40 filing records in this dataset, filed from 2019-06-21 to 2026-09-02. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Cash and cash equivalents: 48.5 million USD 2026-06-30 Source
Exact value

48466000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 76.3 million shares 2026-06-30 Source
Exact value

76285157 shares

Reported share-count change

41.03% · 22.2 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

54091588 shares · 2025-06-30· Source
76285157 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-85 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -19595000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -74880000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -54546000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -18891000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -26179000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-65.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -43267000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -29077000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -60065000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -43267000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -18750000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -34789000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -18750000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

365 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 155000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 65000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 314000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 155000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 8000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 116000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 8000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-66.1 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -43267000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -29077000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -60065000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -43267000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -18750000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -34789000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -18750000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 155000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 65000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 314000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 155000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 8000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 116000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 8000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-09-02.

Financial data available through: 2025-12-31.

Coverage by financial measure

revenue: No compatible figures in this window
Operating income: 8 of 11 periods available· newest 2025-12-31
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 8 of 11 periods available· newest 2025-12-31
Total assets: 8 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2025-12-31
Current assets: 8 of 11 periods available· newest 2025-12-31
Current liabilities: 8 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 8 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 65.16 million

Prior period

−USD 9.73 million

2024-01-01 – 2024-12-31
Current period

−USD 74.88 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-74880000 − -9725000 = -65155000 USD

-9725000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-74880000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Fulcrum Therapeutics, Inc. · 2025-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Year-over-year change in Net income: -65155000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -74880000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1770940 Filing: 000119312526065197 Input fundies:NetIncome: -9725000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1702094 Filing: 000119312526065197
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 57.85 million

Prior period

−USD 2.22 million

2024-01-01 – 2024-12-31
Current period

−USD 60.07 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-60065000 − -2218000 = -57847000 USD

-2218000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-60065000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Fulcrum Therapeutics, Inc. · 2025-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Year-over-year change in Operating cash flow: -57847000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -60065000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1839789 Filing: 000119312526065197 Input fundies:OperatingCashFlow: -2218000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1841574 Filing: 000119312526065197
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+12.9%

Prior period

USD 278,000

2024-01-01 – 2024-12-31
Current period

USD 314,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

314000 − 278000 = 36000 USD

278000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
314000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Fulcrum Therapeutics, Inc. · 2025-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Year-over-year change in Capital expenditure: 36000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 314000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1854156 Filing: 000119312526065197 Input fundies:CapitalExpenditure: 278000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1856024 Filing: 000119312526065197
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.

Values and sources

Revenue values and source evidence
Period	Series	Value	Source evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value	Source evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 32.59 million Exact value Exact value: -32588000 USD 2018-01-01 – 2018-12-31: -32588000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Fulcrum Therapeutics, Inc. · 2018-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Net Income: -32588000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -32588000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000156459020008951/fulc-20191231.xml#134862 Filing: 000156459020008951 The citation records this snapshot. The page link may show a newer release later.	−USD 22.56 million Exact value Exact value: -22562000 USD 2018-01-01 – 2018-12-31: -22562000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Fulcrum Therapeutics, Inc. · 2018-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Operating Cash Flow: -22562000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22562000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000156459020008951/fulc-20191231.xml#155334 Filing: 000156459020008951 The citation records this snapshot. The page link may show a newer release later.	USD 8.98 million Exact value Exact value: 8981000 USD 2018-01-01 – 2018-12-31: 8981000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Fulcrum Therapeutics, Inc. · 2018-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Capital Expenditure: 8981000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8981000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000156459020008951/fulc-20191231.xml#155755 Filing: 000156459020008951 The citation records this snapshot. The page link may show a newer release later.	−USD 31.54 million Calculation and evidence -22562000 − 8981000 USD Exact free cash flow: -31543000 USD 2018-01-01 – 2018-12-31: -22562000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 8981000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Fulcrum Therapeutics, Inc. · 2018-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Free cash flow: -31543000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22562000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000156459020008951/fulc-20191231.xml#155334 Filing: 000156459020008951 Input fundies:CapitalExpenditure: 8981000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000156459020008951/fulc-20191231.xml#155755 Filing: 000156459020008951 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 82.68 million Exact value Exact value: -82677000 USD 2019-01-01 – 2019-12-31: -82677000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Fulcrum Therapeutics, Inc. · 2019-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Net Income: -82677000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -82677000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029682/fulc-20201231.htm#708677 Filing: 000095017023029682 The citation records this snapshot. The page link may show a newer release later.	−USD 39.48 million Exact value Exact value: -39483000 USD 2019-01-01 – 2019-12-31: -39483000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Fulcrum Therapeutics, Inc. · 2019-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Operating Cash Flow: -39483000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39483000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029682/fulc-20201231.htm#1031751 Filing: 000095017023029682 The citation records this snapshot. The page link may show a newer release later.	USD 853,000 Exact value Exact value: 853000 USD 2019-01-01 – 2019-12-31: 853000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Fulcrum Therapeutics, Inc. · 2019-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Capital Expenditure: 853000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 853000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029682/fulc-20201231.htm#1047960 Filing: 000095017023029682 The citation records this snapshot. The page link may show a newer release later.	−USD 40.34 million Calculation and evidence -39483000 − 853000 USD Exact free cash flow: -40336000 USD 2019-01-01 – 2019-12-31: -39483000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 853000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Fulcrum Therapeutics, Inc. · 2019-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Free cash flow: -40336000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39483000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029682/fulc-20201231.htm#1031751 Filing: 000095017023029682 Input fundies:CapitalExpenditure: 853000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029682/fulc-20201231.htm#1047960 Filing: 000095017023029682 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 70.82 million Exact value Exact value: -70819000 USD 2020-01-01 – 2020-12-31: -70819000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Fulcrum Therapeutics, Inc. · 2020-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Net Income: -70819000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -70819000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029689/fulc-20211231.htm#586871 Filing: 000095017023029689 The citation records this snapshot. The page link may show a newer release later.	−USD 53.66 million Exact value Exact value: -53655000 USD 2020-01-01 – 2020-12-31: -53655000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Fulcrum Therapeutics, Inc. · 2020-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Operating Cash Flow: -53655000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -53655000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029689/fulc-20211231.htm#789927 Filing: 000095017023029689 The citation records this snapshot. The page link may show a newer release later.	USD 1.34 million Exact value Exact value: 1342000 USD 2020-01-01 – 2020-12-31: 1342000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Fulcrum Therapeutics, Inc. · 2020-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Capital Expenditure: 1342000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1342000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029689/fulc-20211231.htm#807234 Filing: 000095017023029689 The citation records this snapshot. The page link may show a newer release later.	−USD 55 million Calculation and evidence -53655000 − 1342000 USD Exact free cash flow: -54997000 USD 2020-01-01 – 2020-12-31: -53655000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1342000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Fulcrum Therapeutics, Inc. · 2020-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Free cash flow: -54997000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -53655000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029689/fulc-20211231.htm#789927 Filing: 000095017023029689 Input fundies:CapitalExpenditure: 1342000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029689/fulc-20211231.htm#807234 Filing: 000095017023029689 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 80.85 million Exact value Exact value: -80847000 USD 2021-01-01 – 2021-12-31: -80847000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Fulcrum Therapeutics, Inc. · 2021-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Net Income: -80847000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -80847000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029689/fulc-20211231.htm#695653 Filing: 000095017023029689 The citation records this snapshot. The page link may show a newer release later.	−USD 78.48 million Exact value Exact value: -78478000 USD 2021-01-01 – 2021-12-31: -78478000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Fulcrum Therapeutics, Inc. · 2021-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Operating Cash Flow: -78478000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -78478000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029689/fulc-20211231.htm#787668 Filing: 000095017023029689 The citation records this snapshot. The page link may show a newer release later.	USD 1.71 million Exact value Exact value: 1713000 USD 2021-01-01 – 2021-12-31: 1713000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Fulcrum Therapeutics, Inc. · 2021-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Capital Expenditure: 1713000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1713000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029689/fulc-20211231.htm#804921 Filing: 000095017023029689 The citation records this snapshot. The page link may show a newer release later.	−USD 80.19 million Calculation and evidence -78478000 − 1713000 USD Exact free cash flow: -80191000 USD 2021-01-01 – 2021-12-31: -78478000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1713000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Fulcrum Therapeutics, Inc. · 2021-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Free cash flow: -80191000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -78478000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029689/fulc-20211231.htm#787668 Filing: 000095017023029689 Input fundies:CapitalExpenditure: 1713000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017023029689/fulc-20211231.htm#804921 Filing: 000095017023029689 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 109.87 million Exact value Exact value: -109871000 USD 2022-01-01 – 2022-12-31: -109871000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Fulcrum Therapeutics, Inc. · 2022-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Net Income: -109871000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -109871000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017024021074/fulc-20231231.htm#1592198 Filing: 000095017024021074 The citation records this snapshot. The page link may show a newer release later.	−USD 97.05 million Exact value Exact value: -97050000 USD 2022-01-01 – 2022-12-31: -97050000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Fulcrum Therapeutics, Inc. · 2022-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Operating Cash Flow: -97050000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -97050000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017024021074/fulc-20231231.htm#1701855 Filing: 000095017024021074 The citation records this snapshot. The page link may show a newer release later.	USD 1.96 million Exact value Exact value: 1963000 USD 2022-01-01 – 2022-12-31: 1963000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Fulcrum Therapeutics, Inc. · 2022-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Capital Expenditure: 1963000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1963000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017024021074/fulc-20231231.htm#1712612 Filing: 000095017024021074 The citation records this snapshot. The page link may show a newer release later.	−USD 99.01 million Calculation and evidence -97050000 − 1963000 USD Exact free cash flow: -99013000 USD 2022-01-01 – 2022-12-31: -97050000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1963000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Fulcrum Therapeutics, Inc. · 2022-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Free cash flow: -99013000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -97050000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017024021074/fulc-20231231.htm#1701855 Filing: 000095017024021074 Input fundies:CapitalExpenditure: 1963000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017024021074/fulc-20231231.htm#1712612 Filing: 000095017024021074 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 97.34 million Exact value Exact value: -97335000 USD 2023-01-01 – 2023-12-31: -97335000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Fulcrum Therapeutics, Inc. · 2023-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Net Income: -97335000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -97335000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017025026068/fulc-20241231.htm#1692061 Filing: 000095017025026068 The citation records this snapshot. The page link may show a newer release later.	−USD 90.97 million Exact value Exact value: -90965000 USD 2023-01-01 – 2023-12-31: -90965000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Fulcrum Therapeutics, Inc. · 2023-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Operating Cash Flow: -90965000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -90965000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017025026068/fulc-20241231.htm#1834239 Filing: 000095017025026068 The citation records this snapshot. The page link may show a newer release later.	USD 508,000 Exact value Exact value: 508000 USD 2023-01-01 – 2023-12-31: 508000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Fulcrum Therapeutics, Inc. · 2023-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Capital Expenditure: 508000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 508000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017025026068/fulc-20241231.htm#1847686 Filing: 000095017025026068 The citation records this snapshot. The page link may show a newer release later.	−USD 91.47 million Calculation and evidence -90965000 − 508000 USD Exact free cash flow: -91473000 USD 2023-01-01 – 2023-12-31: -90965000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 508000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Fulcrum Therapeutics, Inc. · 2023-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Free cash flow: -91473000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -90965000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017025026068/fulc-20241231.htm#1834239 Filing: 000095017025026068 Input fundies:CapitalExpenditure: 508000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000095017025026068/fulc-20241231.htm#1847686 Filing: 000095017025026068 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 9.73 million Exact value Exact value: -9725000 USD 2024-01-01 – 2024-12-31: -9725000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Fulcrum Therapeutics, Inc. · 2024-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Net Income: -9725000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9725000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1702094 Filing: 000119312526065197 The citation records this snapshot. The page link may show a newer release later.	−USD 2.22 million Exact value Exact value: -2218000 USD 2024-01-01 – 2024-12-31: -2218000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Fulcrum Therapeutics, Inc. · 2024-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Operating Cash Flow: -2218000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2218000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1841574 Filing: 000119312526065197 The citation records this snapshot. The page link may show a newer release later.	USD 278,000 Exact value Exact value: 278000 USD 2024-01-01 – 2024-12-31: 278000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Fulcrum Therapeutics, Inc. · 2024-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Capital Expenditure: 278000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 278000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1856024 Filing: 000119312526065197 The citation records this snapshot. The page link may show a newer release later.	−USD 2.5 million Calculation and evidence -2218000 − 278000 USD Exact free cash flow: -2496000 USD 2024-01-01 – 2024-12-31: -2218000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 278000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Fulcrum Therapeutics, Inc. · 2024-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Free cash flow: -2496000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2218000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1841574 Filing: 000119312526065197 Input fundies:CapitalExpenditure: 278000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1856024 Filing: 000119312526065197 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 74.88 million Exact value Exact value: -74880000 USD 2025-01-01 – 2025-12-31: -74880000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Fulcrum Therapeutics, Inc. · 2025-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Net Income: -74880000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -74880000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1770940 Filing: 000119312526065197 The citation records this snapshot. The page link may show a newer release later.	−USD 60.07 million Exact value Exact value: -60065000 USD 2025-01-01 – 2025-12-31: -60065000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Fulcrum Therapeutics, Inc. · 2025-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Operating Cash Flow: -60065000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -60065000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1839789 Filing: 000119312526065197 The citation records this snapshot. The page link may show a newer release later.	USD 314,000 Exact value Exact value: 314000 USD 2025-01-01 – 2025-12-31: 314000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Fulcrum Therapeutics, Inc. · 2025-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Capital Expenditure: 314000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 314000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1854156 Filing: 000119312526065197 The citation records this snapshot. The page link may show a newer release later.	−USD 60.38 million Calculation and evidence -60065000 − 314000 USD Exact free cash flow: -60379000 USD 2025-01-01 – 2025-12-31: -60065000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 314000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Fulcrum Therapeutics, Inc. · 2025-12-31 Fulcrum Therapeutics, Inc. (edgar:1680581) Free cash flow: -60379000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:36:26Z Snapshot: 2a2bd7035a5c4aac1d21e7453001a796ff15b0150db0d3de31e1d2268349bb4b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1680581?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -60065000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1839789 Filing: 000119312526065197 Input fundies:CapitalExpenditure: 314000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm#1854156 Filing: 000119312526065197 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

40 filings · 1,660 latest values · 1,660 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001680581, 1680581, FULC, edgar:1680581

Also known as FULCRUM THERAPEUTICS, INC., FULCRUM THERAPEUTICS, INC., Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc.

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

Growth

Profit and cash

Balance sheet

Cash generation